Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Compugen Signs Novartis to Multimillion Dollar LEADS License

NEW YORK, Aug. 2 – Compugen has licensed its LEADS computational biology platform to Novartis, the company announced on Thursday.

The deal, which will run for one year with the option for Novartis to extend two additional years, also includes a proprietary DNA chip design to represent Novartis’ transcriptome database. The deal is worth a "few million dollars" Compugen CEO Mor Amitai told GenomeWeb.

"For us this is a big deal," said Amitai. "Financially, it is substantial, and it [also] means working with one of the best functional genomics groups in the world. It is an imporant validation for us and our technologies." Amitai added that the agreement would allow Compugen to improve its tools based on Novartis' feedback.

The LEADS bioinformatics platform incorporates genomics and proteomics tools and public and proprietary databases. Other licensees include Human Genome Sciences and Pfizer.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.